Competition and antitrust

Bell Gully’s Competition team is involved in high profile competition matters in New Zealand.

Our team is recognised by clients and independent commentators for providing leading advice on the most complex and high-profile competition and anti-trust issues in the market.

Global Competition Review's GCR 100 – a guide to the world's top competition law practices – has recognised Bell Gully as an elite practice (its highest ranking in New Zealand) for the past 19 years. Chambers Asia Pacific’s 2022 edition highlights the competition expertise of four members of Bell Gully’s competition law team, with rankings that include a Band 1 partner and two Band 3 partners.

Work highlights

Mylan N.V merger with Upjohn
Advised Mylan N.V. on its successful merger with Upjohn to form Viatris. Mylan was a US-based global pharmaceutical company that developed, licensed, manufactured, and distributed branded generic and specialty pharmaceuticals. Upjohn was the division of Pfizer that operated Pfizer’s off-patent branded and generic established medicines business. The matter involved working closely with instructing counsel overseas and included successfully negotiating and executing a divestment package to remedy the Commerce Commission’s concerns and obtain formal clearance.

Elanco Animal Health Incorporated acquisition
Advised Elanco Animal Health Incorporated on its agreement with Bayer AG to acquire its animal health business in a transaction worth US$6.9 billion. The matter involved working closely with instructing counsel overseas and included successfully negotiating and executing a divestment package to remedy the Commerce Commission’s concerns and obtain formal clearance.

"​The team is able to throw itself into complex projects and provide the support we need to generate successful outcomes. It’s also agile enough to provide a high-level view which gets to the nub of the issues when we need a quick turnaround on an issue."

The Legal 500 Asia Pacific 2024 ​- Tier 1